CoChat

C Cell Hyperplasia/Neoplasia

LiVolsi, V. A. · 1997 · Journal of Clinical Endocrinology & Metabolism
Cited by 110

The DOI matches its Crossref record.

Abstract

C cell hyperplasia of the thyroid was defined in the early 1970’s as a lesion associated with familial medullary thyroid carcinoma and multiple endocrine neoplasia (MEN), type II and IIB. It is a genetically defined event associated with ret oncogene mutations of specific codons. Pathologically, C cell hyperplasia in the familial setting of an inherited autosomal dominant process is found most prominently in the upper two thirds of the thyroid gland in the lateral lobes. In this type of C cell hyperplasia, the C cells are noted as groups of clear large cells in a peri- or parafollicular location on hematoxylin and eosin staining. Sometimes the cytologic features of the C cells show atypia including nuclear atypia. In familial associated C cell hyperplasia, the C cells may be found in other areas of the gland, although very rarely in the isthmus. In these conditions, the evidence of C cell hyperplasia correlates well with elevations of serum calcitonin either basal or after stimulation by pentagastrin or calcium. The term C cell hyperplasia has been challenged by Carney et al. (1) who state that the lesion is really preinvasive carcinoma. They prefer the term C cell disease rather than C cell hyperplasia. Indeed, familial C cell hyperplasia is a preneoplastic lesion and constitutes carcinoma in situ of the thyroid gland parafollicular cells. In broad pathologic terms, the concept of carcinoma in situ (CIS) represents the accumulation of various genetic events from a normal epithelium to a fully malignant one. These genetic events are manifested microscopically by increasing cytologic atypia, nuclear anaplasia, easily identified mitotic activity, abnormal mitotic figures, and on occasion, necrosis. Changes in vascularity, so called angiogenesis, also occur. The CIS concept is best illustrated in uterine cervix squamous carcinoma and duct carcinoma of the breast. In each of these situations (as in other epithelia in the human body that can give rise to invasive cancers), the diagnosis of in situ carcinoma by established pathologic criteria is relatively straightforward. The clinical meaning and therapy have also been well defined. It is known from large and long-term follow-up epidemiological studies, as well as studies in which the diagnosis of CIS was not correctly identified initially (this is especially true in the breast), that a significant percentage of cases of CIS will progress through additional presumably genetic mutations to breach the light microscopy basement membrane and invade the underlying stroma of the organ of origin. Beginning as microinvasive carcinoma and ending as fully invasive carcinoma, this process continues with ultimate development of metastatic disease. It has been shown that even so called microinvasive carcinomas can on occasion metastasize to regional lymph nodes, although the smaller the focus of microinvasion, the less risk of this occurrence. In the background of this familial setting, C cell hyperplasia is, in fact, C cell carcinoma in situ or C cell neoplasia. Gill et al. (2) describe early invasion (medullary microcarcinoma) in very young patients with familial C cell hyperplasia. Some of these early carcinomas are capable of metastasizing (2). Komminoth et al. (3) identified differences between so called primary C cell hyperplasia associated with familial medullary carcinoma, by immunohistochemical staining for expression of polysialic acid (a post-translation modification of neural cell adhesion molecule). This is identified in primary C cell hyperplasia and in medullary thyroid carcinoma. It is not found immunohistochemically in other thyroid tumors, malignant or benign, or in so called secondary C cell hyperplasia (see below) or normal C cells. These authors suggest that this protein is a marker for medullary carcinoma and may be able to distinguish between primary and secondary C cell hyperplasia. It is still debatable how easy it is for pathologists to identify the lower limit of medullary carcinoma, that is, microinvasive medullary thyroid carcinoma and the upper limit of C cell hyperplasia/C cell neoplasia. DeLellis and Wolfe (4) note that C cell hyperplasia ranges from a diffuse increase in the cells to nodules of C cells that eventually replace follicles so that they become devoid of colloid. They indicate that once the basement membrane of the follicle is breached, medullary carcinoma should be diagnosed; however, Carney et al. (1) note that it is not always obvious that the basement membrane has been crossed. In addition, it is known that C cell hyperplasia will show diffuse and intense immunereactivity for calcitonin, greater than that for medullary carcinoma (4). However, this is a matter of degree and also of technical expertise; in any individual case, the immunostaining intensity may not be helpful in distinguishing early invasion, that is medullary carcinoma, from florid C cell hyperplasia/C cell neoplasia. McDermott et al. (5) indicate that immunostain

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.82.1.39

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
LiVolsi, V. A.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1997-01-01
Volume
82
Issue
1
Pages
39-41
ISSN
0021-972X (ISSN-L)
OpenAlex
W2035003798
Cited by
110
References
0
FWCI
1.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.